, Tracking Stock Market Picks
Enter Symbol:
Anthera Pharmaceuticals, Inc. (ANTH) [hlAlert]

down 85.63 %

Anthera Pharmaceuticals, Inc. (ANTH) rated Buy with price target $14 by Deutsche Bank

Posted on: Tuesday,  Nov 1, 2011  1:25 PM ET by Deutsche Bank

Deutsche Bank rated Buy Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) on 11/01/2011, when the stock price was $52.56. Since
then, Anthera Pharmaceuticals, Inc. has lost 85.64% as of 01/13/2016's recent price of $7.55.
If you would have followed this Deutsche Bank's recommendation on ANTH, you would have lost 85.63% of your investment in 1534 days.

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Deutsche Bank is one of the largest European fund managers. DWS was founded in 1956 and is an integral part of the Asset Management division of Deutsche Bank. This division is one of the largest global asset managers.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2011 1:25 PM Buy
52.56 112.00
as of 12/30/2011
1 Week up  1.32 %
1 Month up  5.49 %
3 Months down  -6.54 %
1 YTD down  -6.54 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy